Antiatherosclerotic effect of farnesoid X receptor

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 2, 2009, Pages

  Mencarelli, Andrea ^a   Renga, Barbara ^a   Distrutti, Eleonora ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bile acids; Liver; Macrophages; Nuclear receptor

Indexed keywords

ABC TRANSPORTER A1; CARDIOVASCULAR AGENT; CD11B ANTIGEN; CD36 ANTIGEN; CHENODEOXYCHOLIC ACID DERIVATIVE; CHOLESTEROL; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INT 747; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ABCG1 PROTEIN, HUMAN; APOLIPOPROTEIN E; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; DNA BINDING PROTEIN; DRUG DERIVATIVE; FARNESOID X-ACTIVATED RECEPTOR; LIGAND; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL HETERODIMER PARTNER PROTEIN; SREBF1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROSCLEROTIC EFFECT; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CELL ISOLATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; EFFUSION; ENZYME ACTIVATION; GENE INDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID ANALYSIS; LIPID METABOLISM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; ANIMAL; AORTA; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG POTENTIATION; FEMALE; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD36; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR AGENTS; CHENODEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYPERLIPIDEMIAS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGANDS; LIPIDS; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61949324741     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01075.2008     Document Type: Article

References (49)

1. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med 8: 1218 - 1226, 2002.
2. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22: 347 - 351, 1999.
3. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Hörkkö S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL. Scavenger receptors, oxidized LDL, atherosclerosis. Ann NY Acad Sci 947: 214 - 222, 2001.
4. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22: 336 - 345, 1999.
5. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7: 48 - 52, 2001.
6. Chodouri RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2: 309 - 31, 2005.
7. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109: 961 - 971, 2002.
8. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127: 1497 - 1512, 2004.
9. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313: 604 - 612, 2005.
10. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517 - 526, 2000.
11. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation, and atherosclerosis development. Biochim Biophys Acta 1761: 1401 - 1409, 2006.
12. Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 293: 338 - 343, 2002.
13. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 46: 2595 - 2604, 2005.
14. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 6: 986 - 994, 1996.
15. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 101: 2331 - 2339, 1998.
16. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87: 2020 - 2028, 1996.
17. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'Connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119: 299 - 309, 2004.
18. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9: 213 - 219, 2003.
19. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99: 7604 - 7609, 2002.
20. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15: 1720 - 1728, 2001.
21. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 7: 10638 - 10647, 2000.
22. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, Sinal CJ. The farnesoid X receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278: 2563 - 2570, 2003.
23. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201 - 2207, 2003.
24. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 16: 19 - 25, 2005.
25. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523 - 531, 2000.
26. 0Libby P. Inflammation in atherosclerosis. Nature 420: 868 - 874, 2002.
27. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 12: 489 - 495, 2001.
28. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6: 507 - 515, 2000.
29. Mak PA, Kast-Woelbern HR, Anisfeld AM, Edwards PA. Identification of PLTP as an LXR target gene and ApoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 43: 2037 - 2041, 2002.
30. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 21: 1362 - 1365, 1999.
31. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7: 41 - 47, 2001.
32. Nakagawa T, Nozaki S, Nishida M, Yakub JM, Tomiyama Y, Nakata A, Matsumoto K, Funahashi T, Kameda-Takemura K, Kurata Y, Yamashita S, Matsuzawa Y. Oxidized LDL increases and interferon- gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18: 1350 - 1357, 1998.
33. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14: 133 - 140, 1994.
34. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68: 231 - 240, 1987.
35. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science 21: 1365 - 1368, 1999.
36. Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, Fiorucci S, Clerici C, Gioiello A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure- activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 47: 4559 - 4569, 2001.
37. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 48: 5383 - 5403, 2005.
38. Russell DW, Setchell KDR. Bile acid biosynthesis. Biochemistry 31: 4737 - 4749, 1992.
39. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assamann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22: 352 - 355, 1999.
40. Schote AB, Turner JD, Schiltz J, Muller CP. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 44: 1436 - 1445, 2007.
41. Shimomura I, Shimano H, Korn BS, Bashmakov Y, Horton JD. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 273: 35299 - 35306, 1998.
42. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731 - 744, 2000.
43. Takahashi K, Kimura Y, Nagata K, Yamamoto A, Matsuo M, Ueda K. ABC proteins: key molecules for lipid homeostasis. Med Mol Morphol 38: 2 - 12, 2005.
44. Tanaka AR, Abe-Dohmae S, Ohnishi T, Aoki R, Morinaga G, Okuhira K, Ikeda Y, Kano F, Matsuo M, Kioka N, Amachi T, Murata M, Yokoyama S, Ueda K. Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem 278: 8815 - 8819, 2003.
45. Urizar NL, Dowhan DH, Moore DD. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 275: 39313 - 39317, 2000.
46. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res 47: 2433 - 2443, 2006.
47. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543 - 553, 1999.
48. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101: 9774 - 9779, 2004.
49. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408 - 1418, 2004.